Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray

Meltzer, Eli O.; Charous, B.L.; Busse, William W.; Zinreich, S. James; Lorber, Richard; Danzig, Melvyn R.

doi:10.1067/mai.2000.109056

Cited by 136 publications

(132 citation statements)

References 18 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, there are several RCTs in adolescents and adults, most of which do show significant differences compared with placebo or active comparator that favor intranasal steroids in the reduction of symptoms and the patient' s global assessment of overall improvement. [80][81][82][83][84][85] Several studies in adults with acute bacterial sinusitis provide data supporting the use of intranasal steroids as either monotherapy or adjuvant therapy to antibiotics. 81,86 Only one study did not show efficacy.…”

Section: Intranasal Steroidsmentioning

confidence: 99%

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Wald,

Applegate,

Bordley

et al. 2013

Pediatrics

446

368

View full text Add to dashboard Cite

OBJECTIVE: To update the American Academy of Pediatrics clinical practice guideline regarding the diagnosis and management of acute bacterial sinusitis in children and adolescents. METHODS: Analysis of the medical literature published since the last version of the guideline (2001). RESULTS: The diagnosis of acute bacterial sinusitis is made when a child with an acute upper respiratory tract infection (URI) presents with (1) persistent illness (nasal discharge [of any quality] or daytime cough or both lasting more than 10 days without improvement), (2) a worsening course (worsening or new onset of nasal discharge, daytime cough, or fever after initial improvement), or (3) severe onset (concurrent fever [temperature ≥39°C/102.2°F] and purulent nasal discharge for at least 3 consecutive days). Clinicians should not obtain imaging studies of any kind to distinguish acute bacterial sinusitis from viral URI, because they do not contribute to the diagnosis; however, a contrast-enhanced computed tomography scan of the paranasal sinuses should be obtained whenever a child is suspected of having orbital or central nervous system complications. The clinician should prescribe antibiotic therapy for acute bacterial sinusitis in children with severe onset or worsening course. The clinician should either prescribe antibiotic therapy or offer additional observation for 3 days to children with persistent illness. Amoxicillin with or without clavulanate is the first-line treatment of acute bacterial sinusitis. Clinicians should reassess initial management if there is either a caregiver report of worsening (progression of initial signs/symptoms or appearance of new signs/symptoms) or failure to improve within 72 hours of initial management. If the diagnosis of acute bacterial sinusitis is confirmed in a child with worsening symptoms or failure to improve, then clinicians may change the antibiotic therapy for the child initially managed with antibiotic or initiate antibiotic treatment of the child initially managed with observation. CONCLUSIONS: Changes in this revision include the addition of a clinical presentation designated as “worsening course,” an option to treat immediately or observe children with persistent symptoms for 3 days before treating, and a review of evidence indicating that imaging is not necessary in children with uncomplicated acute bacterial sinusitis.

show abstract

Section: Intranasal Steroidsmentioning

confidence: 99%

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Wald,

Applegate,

Bordley

et al. 2013

Pediatrics

446

368

View full text Add to dashboard Cite

show abstract

“…113,114 Studies in patients with maxillary, recurrent, or acute sinusitis have found that use of flunisolide or mometasone as adjunctive treatment is well tolerated and significantly more effective for the reduction of symptoms than antibiotic therapy alone. [115][116][117] A University of Michigan Health System Guideline for Clinical Care has cited high-dose INS spray formulations as likely to be effective in acute and chronic rhinosinusitis, but has indicated that more research is required. 118 Only limited clinical evidence is currently available to support the role of INS as monotherapy for acute rhinosinusitis.…”

Section: Acute Rhinosinusitis and Nasal Polyposis: Association With Amentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

“…3 Several studies conclude that intranasal corticosteroids (with or without antibiotics) are beneficial in ARS patients and are equally or more effective than antibiotics alone. [4][5][6][7][8] Currently, only one intranasal corticosteroidmometasone furoate nasal spray (MFNS) -is approved for ARS, 9 and this indication is limited to Canada. Fluticasone furoate, an enhanced-affinity glucocorticoid, has been developed as an intranasal spray for the treatment of allergic rhinitis (AR).…”

mentioning

confidence: 99%

Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study

Keith

Dymek²,

Pfaar

et al. 2012

Primary Care Respiratory Journal

View full text Add to dashboard Cite

show abstract

Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray

Cited by 136 publications

References 18 publications

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study

Contact Info

Product

Resources

About